Your browser doesn't support javascript.
loading
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor).
Siddiqui, Bilal A; Chapin, Brian F; Jindal, Sonali; Duan, Fei; Basu, Sreyashi; Yadav, Shalini S; Gu, Ai-Di; Espejo, Alexsandra B; Kinder, Michelle; Pettaway, Curtis A; Ward, John F; Tidwell, Rebecca S S; Troncoso, Patricia; Corn, Paul G; Logothetis, Christopher J; Knoblauch, Roland; Hutnick, Natalie; Gottardis, Marco; Drake, Charles G; Sharma, Padmanee; Subudhi, Sumit K.
Affiliation
  • Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Chapin BF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jindal S; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Duan F; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Basu S; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yadav SS; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gu AD; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Espejo AB; The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kinder M; Janssen Research & Development, Spring House, Pennsylvania, USA.
  • Pettaway CA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ward JF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tidwell RSS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Troncoso P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Corn PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Logothetis CJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Knoblauch R; Janssen Research & Development, Spring House, Pennsylvania, USA.
  • Hutnick N; Janssen Research & Development, Spring House, Pennsylvania, USA.
  • Gottardis M; Janssen Research & Development, Spring House, Pennsylvania, USA.
  • Drake CG; Janssen Research & Development, Spring House, Pennsylvania, USA.
  • Sharma P; Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Subudhi SK; Department of Urology, Columbia University Medical Center, New York, New York, USA.
J Immunother Cancer ; 11(3)2023 03.
Article in En | MEDLINE | ID: mdl-36948506
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Agents Limits: Humans / Male Language: En Journal: J Immunother Cancer Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Agents Limits: Humans / Male Language: En Journal: J Immunother Cancer Year: 2023 Document type: Article Affiliation country: